• Mashup Score: 0

    Osimertinib has emerged as the standard of care for patients with EGFR-mutated non–small cell lung cancer, but the need for novel agents is underscored as disease progression on the agent is inevitable.

    Tweet Tweets with this article
    • Bispecific antibodies, antibody-drug conjugates, EGF vaccines, and fourth-generation EGFR TKIs are all under development and showing early potential to enrich the treatment paradigm @UCD_Cancer @gotoPER #ILCC2021 #lcsm https://t.co/1X3gzLza4h https://t.co/KAT61Beui8

  • Mashup Score: 0

    Many checkpoint inhibitors are currently under investigation in combination with concurrent radiotherapy in stage III non–small cell lung cancer, which experts propose could have practice-changing implications.

    Tweet Tweets with this article
    • Many checkpoint inhibitors are currently under investigation in combination w/ concurrent radiotherapy in stage III NSCLC, which experts propose could have practice-changing implications @EnriquetaFelip @vallhebron @gotoPER #ILCC2021 #lcsm https://t.co/XbAeBOUdJY

  • Mashup Score: 0

    Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years, explained Karen L. Reckamp, MD, who added that research regarding predictive co-mutations, acquired resistance, and combination strategies is expected to propel the utility of these agents even further.

    Tweet Tweets with this article
    • Significant advances have been made regarding the development of KRAS G12C inhibitors in non–small cell lung cancer in recent years @ReckampK @CedarsSinai @gotoPER #ILCC2021 #lcsm https://t.co/6g9QJlSjkM

  • Mashup Score: 0

    Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab.

    Tweet Tweets with this article
    • Bispecific antibodies have become an interesting new class of agents in the lung cancer pipeline, most recently with the developments of amivantamab-vmjw, zenocutuzumab, and tarlatamab @giorgioscaglio3 @gotoPER #ILCC2021 #lcsm https://t.co/3CPzBIAYpy

  • Mashup Score: 0

    RET inhibitors displayed promising efficacy and a tolerable safety profile in patients with non–small cell lung cancer harboring RET alterations.

    Tweet Tweets with this article
    • The future of RET inhibitors in NSCLC will depend on a deeper understanding of acquired mutations and the development of strategies to circumvent bypass resistance @ReckampK @CedarsSinai @gotoPER #ILCC2021 #lcsm https://t.co/ZrlTcg8MD4 https://t.co/VSlUhu83rs